Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
NEW YORK, Dec. 21, 2016 -- TikaMobile, Inc., a cloud-based mobile and analytics software provider for the life sciences industry, today announced that ZS Pharma, a member of the AstraZeneca Group, focused on using its proprietary ion-trap technology to develop new treatments addressing unmet needs in the pharma and medical community, will deploy the TikaPharma solution to help launch their new product ZS-9 as a new therapeutic option for hyperkalemia. TikaPharma will provide the ZS Pharma sales team with actionable intelligence and analysis at the customer and territory levels accessible via both iPad and web to help them drive revenue.
With its world-class team and extensive requirements, ZS Pharma required a robust solution to deliver on its vision to have a profound impact in the hyperkalemia market. This relationship with TikaMobile helps address ZS Pharma’s unmet analytics and mobility needs.
Yasser Ali, Vice President, Business Analytics at ZS Pharma said, “At ZS Pharma, we’re dedicated to leveraging innovative approaches to transform patient care. We’ve adopted this mindset within the Commercial team when it comes to the analytics we provide to our sales team. In TikaMobile, we found a partner equally dedicated to innovation in mobile intelligence and analytics. New Biopharma drug launches require near real-time insights on new diagnoses, reimbursement challenges, source of business, etc. We feel that the TikaPharma platform is ideal to deliver this intelligence due to its agile nature and exceptional user experience.”
Implementing TikaPharma will help maximize the effectiveness of ZS Pharma’s go-to-market efforts by providing their sales reps the actionable insights they need to stay one step ahead of their competition. “We are excited to work with the ZS Pharma team,” said Manish Sharma, CEO at TikaMobile. “Our vision is to be the leading provider of mobile intelligence and analytics solutions that deliver real-time, on-demand access to the business insights that life sciences sales teams need to drive revenues and be market leaders.”
About TikaMobile
TikaMobile Inc. is leading innovations in cloud based mobile and analytics SaaS solutions for the life sciences industry. Dedicated to customer success, TikaMobile’s real time recommendation analytics go beyond CRM to give commercial teams and field sales ongoing actionable intelligence. Our powerful, yet agile applications for Pharmaceutical and Medical Device organizations are easy-to-use, easy to deploy, and can accommodate companies of all sizes. For more information visits us at www.tikamobile.com.
Contact Cliona Barry [email protected]
